No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

itSpray Announces BOOSTit with New Ingredients Elderberry and Monk Fruit Coming Soon

Editor: What To Know

  • We expect a lot of interest in BOOSTit as our customers have been awaiting the arrival of the new formula.
  • Monk fruit is able to provide a sweet flavor without the calories, and is rich in antioxidants.
  • Elderberry (scientific name is sambucus), the first new ingredient in BOOSTit, comes from the European elder tree and is a type of flowering plant.

February 8, 2021

itSpray founder Kimberly Stiele said, “At itSpray we strive to give you the best solutions for your total health needs. We continue to improve our products to help you pursue a healthier lifestyle with ease, including immune support, sustained energy, and sleep solutions. Which is why Drug Store News has named BOOSTit a Who’s Who of Immunity products.”

BOOSTit is a solution for immune support and contains many essential vitamins. These include vitamins A, C, D, B-12 and B2. These vitamins along with other natural ingredients, encourage white blood cell production and strengthen the immune system.

Elderberry (scientific name is sambucus), the first new ingredient in BOOSTit, comes from the European elder tree and is a type of flowering plant. According to Medical News Today, the dark purple berries and flowers contain many antioxidants that support the immune, including vitamin C, vitamin A, and iron. In addition to immune support, iron helps with energy, focus, digestion, and body temperature maintenance.

Monk fruit sweetener has replaced sucralose, the sweetener previously used in BOOSTit. Monk fruit, as defined by monkfruit.org, is a small, sub-tropical melon that has been cultivated for centuries. It is a super-fruit that acts as a natural sweetener. Monk fruit is able to provide a sweet flavor without the calories, and is rich in antioxidants. Since 2009, more than 800 products have used monk fruit sweetener. A few of the health benefits of monk fruit include weight loss, protection against diabetes, and immune support, according to Conserve Energy Future.

We expect a lot of interest in BOOSTit as our customers have been awaiting the arrival of the new formula. Your body works hard for you and will thank you for treating it with care it deserves.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy